NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-07-23
Reading ASTH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is positioned as a stable growth opportunity within the healthcare sector. The current thesis state is intact, supported by strong recent financial performance and a stable management team.
The market currently prices ASTH at a premium compared to peers, indicating that it is seen as expensive. There is a slight expectations gap, suggesting that the market anticipates continued strong performance but is cautious about potential volatility.
Management is focused on achieving significant revenue growth and improving operating income, which are on track. However, free cash flow improvement is mixed, and there is a low probability of missing earnings expectations, though recent industry trends may introduce some risk.
The long-term thesis hinges on the performance of sector bellwethers like HCA, THC, and DVA. If these companies continue to perform well, it could provide a favorable backdrop for ASTH. Conversely, any negative guidance from these peers could impact ASTH's momentum.
In the next 1 to 3 years, ASTH's performance will depend on its ability to navigate sector dynamics and execute on its growth priorities. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings beat was a positive sign. However, ASTH has dropped sharply, which may mean the market is changing its view. This price drop suggests a need to reassess the reasons to own the stock.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Hitting this revenue target shows strong growth. It matches management's full-year guidance.
Confirms:Q2 2026 revenue reported at or above $1 billion.
Disproves:Q2 2026 revenue reported below $965 million.
Why it matters: This report will give important insights into revenue growth and how the company performs.
Confirms one read:Earnings report shows revenue growth of at least 56% year over year.
Confirms the other:Earnings report shows revenue growth below 50% year over year.
Why it matters: An improvement means better cost control. It also shows better operations.
Confirms:Operating income was over $28.5 million for Q2 2026.
Disproves:Operating income was under $28.5 million for Q2 2026.
Why it matters: This means strong performance and good cost control.
Confirms:Adjusted EBITDA was over $70 million for Q2.
Disproves:Adjusted EBITDA was below $65 million for Q2.
Why it matters: The Chief Medical Officer is leaving. This could change the company’s plans and operations.
Confirms one read:Management has a clear plan to handle the CMO leaving and keep things running.
Confirms the other:There is no clear plan after the CMO's departure.
Why it matters: Filling this job fast could help keep things running smoothly after Dr. Kumar leaves.
Confirms one read:Announcement of a new Chief Medical Officer within the next month.
Confirms the other:No announcement of a new Chief Medical Officer by the next earnings call.
Why it matters: Reaching this target shows good capital management. It helps future growth plans.
Confirms:Free cash flow reported at or above $105 million for Q2 2026.
Disproves:Free cash flow reported below $100 million for Q2 2026.
Why it matters: This milestone shows Astrana values care based on results. It impacts total profits.
Confirms:The reported revenue from full-risk contracts is 80% or more.
Disproves:The reported revenue from full-risk contracts is below 75%.
